Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 411 to 420 of 1090 total matches.
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013 (Issue 1415)
posterior leukoencephalopathy
syndrome (RPLS) has been reported.
DRUG INTERACTIONS — Regorafenib ...
Regorafenib (Stivarga – Bayer), a multikinase inhibitor,
has been approved by the FDA for treatment of
patients with metastatic colorectal cancer previously
treated with multiple other regimens specified in the
labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or
metastatic gastrointestinal stromal tumor (GIST).
Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Feb 06, 2012 (Issue 1383)
Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1383)
February 6, 2012
www.medicalletter.org ...
The FDA has approved crizotinib (Xalkori – Pfizer), an oral tyrosine kinase inhibitor, for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK) translocation, which is found in about 4-5% of lung cancers. A diagnostic test (Vysis ALK Break Apart FISH Probe Kit – Abbott Molecular) is available to detect translocations of the ALK gene in tumor samples; these translocations occur predominantly in nonsmokers with adenocarcinoma.
Almotriptan (Axert) and Frovatriptan (Frova) for Migraine
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002 (Issue 1124)
arrhythmias, hypertension and stroke.
DRUG INTERACTIONS — Ergot alkaloids may increase or prolong vasospastic ...
Almotriptan (Axert - Pharmacia), and Frovatriptan (Frova - Elan) have been approved by the FDA for oral treatment of migraine headache (Drugs of Choice from The Medical Letter 2001, page 131.).
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
with tadalafil.
DRUG INTERACTIONS — Tadalafil is metabolized
mainly by CYP3A4; inhibitors of that enzyme ...
The FDA has approved use of tadalafil (Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
with coronary artery disease.9
DRUG INTERACTIONS — Vonoprazan may decrease
serum concentrations of drugs ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
dysgeusia, diarrhea, hypertension, and myalgia.
DRUG INTERACTIONS ― Both nirmatrelvir and
ritonavir ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Substituting For Cerivastatin (Baycol)
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
with concurrence
of serious infections or hypothyroidism.
DRUG INTERACTIONS — The risk of myopathy may increase ...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
(no evidence of
harm in animals; no adequate human studies) for use
during pregnancy.
DRUG INTERACTIONS ...
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events in patients with
peripheral arterial disease or a history of myocardial
infarction (MI). It is the first PAR-1 antagonist to be
approved by the FDA.
Zolmitriptan for Migraine
The Medical Letter on Drugs and Therapeutics • Feb 27, 1998 (Issue 1021)
of zolmitriptan.
DRUG INTERACTIONS — Ergot-containing drugs and monoamine oxidase A (MAO-A) inhibitors ...
Zolmitriptan (Zomig - Zeneca), a selective serotonin (5-HT1)-receptor agonist, is now available in the USA for oral treatment of migraine headache. Zomitriptan structurally resembles sumatriptan (Imitrex - Medical Letter 34:91, 1992). Drugs currently used for acute treatment of migraine include injectable, oral and nasal spray formulations of sumaptriptan, injectable dihydroergotamine, dihydroergotamine nasal spray, ergotamine tartrate alone or with caffeine, and various analgesics. Anoterh 5-HT1-receptor agonist, naratriptan (Amerge - Gaxo Wellcome), has been approved by the FDA but has not...
Celecoxib for Arthritis
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999 (Issue 1045)
. It has a half-life of about 11 hours.
DRUG INTERACTIONS — CYP2C9 inhibitors such as zafirlukast (Accolate ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.